The intersection of the pharmaceutical supply chain and national security has been front and center for years with on account of multiple events: such as the widespread shortages of IV fluids in the aftermath of Hurricane Helene, made-in-China contrast media due to pandemic lockdowns, and generic oncology medications after a Food and Drug Administration (FDA) inspection of an Indian manufacturer.

More recently, a Department of Commerce section 232 investigation , an Executive Order shoring up domestic manufacturing, and looming threats of tariffs have raised eyebrows regarding the strength of our nation’s pharmaceutical supply chain and whether it can truly weather preventable shocks.

The answer is no.

Americans can forgo purchasing consumer goods or other items subject to t

See Full Page